ScreenerHero

VTGNVistaGen Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · vistagen.com
0.2440USD-0.04%Mkt Cap: 10.83M $P/E: —

Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline inclu…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap10.83M $
Enterprise Value-33.38M $
Revenue (TTM)1.27M $
Gross Profit1.27M $
Net Income (TTM)-69.69M $
Revenue/Share0.0330 USD
Last Price0.2440 USD
Fiscal Year EndMar 2026
MR QuarterMar 2026
Employees41
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.16
PEG—
EV/EBITDA0.46
EV/Revenue-26.30
P/S8.43
P/B0.27
EPS (TTM)-1.63
EPS (Forward)-1.54
52W Range
0.19801% of range5.140
52W High5.140 USD
52W Low0.1980 USD
Profitability
Gross Margin100.00%
Oper. Margin-3595.05%
EBITDA Margin0.00%
Profit Margin-5491.33%
ROE-196.19%
ROA-143.49%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-66.44M $
CapEx (TTM)151.00K $
FCF Margin-3191.23%
FCF Yield-374.00%
Net Debt-44.36M $
Net Debt/EBITDA0.62
Balance Sheet
Debt/Equity0.03
Current Ratio3.67
Quick Ratio3.55
Book Value/Sh0.8970 USD
Cash/Share1.107 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:30
Split DateJun 7, 2023
Analyst Consensus
Rating3.0 (Hold)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)1.000 USD
Upside (mean)+309.8%
Target Range1.000 USD – 1.000 USD
# Analysts2
Ownership
Shares Out.44.38M
Float35.07M
Insiders0.37%
Institutions39.09%
Short Interest
Short Ratio0.5d
Short % Float4.53%
Short % Out.4.52%
Shares Short2.01M
Short (prev mo.)1.59M
Technical
SMA 500.3512 (-30.5%)
SMA 2001.116 (-78.1%)
Beta0.38
S&P 52W Chg18.16%
Avg Vol (30d)5.07M
Avg Vol (10d)1.26M
Technical Indicators
RSI (14)38.1
MACD-0.0222
MACD Signal-0.0289
MACD Hist.+0.0067
BB Upper0.3022 USD
BB Middle0.2565 USD
BB Lower0.2109 USD
BB Width35.59%
ATR (14)0.0278 USD
Vol Ratio (20d)0.14x